CD47 and neoplasm: Anti-CD47 antibodies have also been reported to strengthen the anti-tumor activity of macrophages (Brierley et al., 2019; Sikic et al., 2019; Jia et al., 2021), and some anti-CD47 mAbs in different tumors are in the clinical trials (NCT02953509, NCT04751383).